Please login to the form below

Fasenra

This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.

AZ says target of $45bn sales by 2023 still achievable

The underlying picture is strong, however, with new medicines like Tagrisso, Imfinzi, Lynparza in cancer, Farxiga in diabetes and Fasenra in severe asthma growing 19% in the first nine months of ... In respiratory, interleukin-5 inhibitor Fasenra

Latest news

Dupixent helps put Sanofi back on growth track

Fasenra (benralizumab) all jostling for market share.
FDA rejects GSK’s Nucala for COPD

Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab). ... In May, AZ’s Fasenra failed a phase III trial in this indication as it was unable to show a benefit compared to placebo reducing exacerbations.
AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Drugs like Fasenra and GlaxoSmithKline’s rival IL-5 inhibitor Nucala (mepolizumab) have emerged as an important treatment option for people with severe asthma characterised by high levels of eosinophils. ... Nucala made £245m ($317m) in the first six
New cancer drugs can’t quite plug the revenue hole at AZ

Fasenra (benralizumab) although overall respiratory sales were flat in the first half at $2.41bn. ... AZ’s decision to price IL-5 inhibitor Fasenra below rival products from GlaxoSmithKline and Teva seems to have helped get the drug moving quickly with
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare. Limited NICE approval for AZ’s asthma drug Fasenra. ... NICE has published draft guidance recommending Fasenra (benralizumab), AstraZeneca’s treatment for people who have severe eosinophilic asthma.

More from news
Approximately 6 fully matching, plus 9 partially matching documents found.

Latest Intelligence

AstraZeneca: building a new ‘open innovation’ pharma company

AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director: Competitive Salary Offered

Account Manager / Account Director: Competative

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Associate Director: £75, 000-90, 000

Senior Medical Writer: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Global Business Development Director – Health Education: excellent commission

Medical Writer: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Business Director: Competitive Salary Offered

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager / Senior Account Manager: 35, 000-40, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager: Competitive Salary Offered

Account Director, Medical Education: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Fendix

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....